Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
Very poor margins and returns
Slightly negative price performance
Risk / Profitability
Risk: High
Profitability: Modest
About
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential...
Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
Very poor margins and returns
Slightly negative price performance
$ 0.41
About
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential...